Home › Funds › Samsara BioCapital, LLC › STRO
Samsara BioCapital, LLC position in STRO
SUTRO BIOPHARMA INC · Health Care
Samsara BioCapital, LLC reported holding 1,062,872 shares of STRO (SUTRO BIOPHARMA INC) in its Q3 2026 13F filing — a position valued at US$17.1M, representing 1.63% of its reported portfolio and ranking #11 among its reported holdings. Samsara BioCapital, LLC has disclosed STRO holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Samsara BioCapital, LLC's STRO position evolved
Samsara BioCapital, LLC first disclosed a stake in STRO in Q3 2023 at 1,675,579 shares (US$5.8M). The position peaked in Q2 2026 at 1,062,872 shares, worth US$35.3M. Across 13 filings, Samsara BioCapital, LLC increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 9 time(s). The most recent filing (Q3 2026) shows 1,062,872 shares valued at US$17.1M. Notable position changes include a 31% increase in Q2 2024 (shares rose 18% over the following quarter), a 91% trim in Q4 2025 (shares rose 115% over the following quarter), a 420% increase in Q1 2026 (shares rose 33% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.68M | $5.81M | New |
| Q4 2023 | 1.68M | $7.19M | Hold |
| Q1 2024 | 1.68M | $9.47M | Hold |
| Q2 2024 | 2.20M | $6.44M | Add |
| Q3 2024 | 2.20M | $7.60M | Hold |
| Q4 2024 | 2.20M | $4.04M | Hold |
| Q1 2025 | 2.20M | $1.43M | Hold |
| Q2 2025 | 2.20M | $1.57M | Hold |
| Q3 2025 | 2.20M | $1.91M | Hold |
| Q4 2025 | 204.50K | $2.37M | Reduce |
| Q1 2026 | 1.06M | $26.48M | Add |
| Q2 2026 | 1.06M | $35.29M | Hold |
| Q3 2026 | 1.06M | $17.12M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About STRO and 13F data
STRO (SUTRO BIOPHARMA INC) is a Health Care company. 34 other funds we track also report a position in STRO — the largest reported positions include BVF INC/IL (US$20.2M), Affinity Asset Advisors, LLC (US$18.6M), PERCEPTIVE ADVISORS LLC (US$15.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding STRO
- BVF INC/IL 1.25M sh · $20.17M · Q3 2026
- Affinity Asset Advisors, LLC 1.15M sh · $18.57M · Q3 2026
- PERCEPTIVE ADVISORS LLC 970.85K sh · $15.64M · Q3 2026
- Kynam Capital Management, LP 872.56K sh · $14.06M · Q3 2026
- Velan Capital Investment Management LP 510.04K sh · $8.22M · Q3 2026
- Merck & Co., Inc. 272.35K sh · $4.39M · Q3 2026
- Elmind Capital, LP 228.26K sh · $3.68M · Q3 2026
- KVP Capital Advisors, LP 226.57K sh · $3.65M · Q3 2026
More on Samsara BioCapital, LLC
FAQ
How long has Samsara BioCapital, LLC held STRO?
Samsara BioCapital, LLC has disclosed STRO holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Samsara BioCapital, LLC's current position in STRO?
As of Q3 2026, Samsara BioCapital, LLC holds 1.06M shares of STRO (SUTRO BIOPHARMA INC), valued at $17.12M, representing 1.63% of its reported portfolio and ranking #11.
Has Samsara BioCapital, LLC been buying or selling STRO?
In the latest 13F filing (Q3 2026), Samsara BioCapital, LLC held unchanged its position in STRO. The position peaked in Q2 2026 at 1.06M shares.
Which other funds hold STRO?
Other major institutional holders of STRO include BVF INC/IL, Affinity Asset Advisors, LLC, PERCEPTIVE ADVISORS LLC, among 34 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.